Abstract Thiazolidinedione (TZD) is a powerful insulin sensitizer in the treatment of type 2 diabetes. It acts as a ligand to the nuclear receptor PPARy (peroxisome proliferator-activated receptor-gamma) and induces transcription of PPARy-responsive genes. TZD controls lipid synthesis and storage in adipose tissue, liver and many other tissues through PPARy. Derivatives of TZD, such as rosiglitazone (Avandia) and pioglitazone (Actos), are more powerful than metformin or berberine in insulin sensitization. Although they have common side elIects such as weight gain and edema, these did not influence their clinical application in general. However, recent findings of risk for congestive heart failure and bladder cancer have significantly impaired their future in many countries. European countries have prohibited those drugs, and US will terminate application of rosiglitazone in clinics and hospitals. The multiple country actions may mark the end of TZD era. As a result, there is a strong demand for identification of TZD substitute in the treatment of type 2 diabetes. In this regard, literature about PPARy ligands and potential TZD substitute are reviewed in this article. Histone deacetylase (HDAC) inhibitor is emphasized as a new class of insulin sensitizer here. Regulators of SiRTI, CREB, NO, p38, ERK and CdkS are discussed in the activation of PPARy.
Introduction
Thiazolidinedione (TZD) is a powerful insulin sensitizer in the treatment of type 2 diabetes, a disease that is associated with obesity and aging through insulin resistance. With prevalence of obesity and increased lifespan in industrial countries, incidence of type 2 diabetes is increased quickly worldwide. In the treatment of type 2 diabetes, restoration of insulin sensitivity is a major strategy. Currently, there are several classes of drugs available in the treatment of insulin resistance. They are metformin, TZDs (Avandia and Actos), berberine, meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-I receptor agonists. Among those, TZD-based drugs are the most powerful medicines among these insulin sensitizers. There are two widely used commercial products derived from TZD, rosiglitazone (Avandia), and pioglitazone (Actos). The two medicines have common side effects such as weight gain and edema. However, rosiglitazone and muraglitazone have recently been reported to increase risk for congestive heart failure and risk for bone fractures!. The heart attack is lethal and not acceptable in the treatment of type 2 diabetes. As a result, the European Medicines Agency (EMA) recommended in September 2010 to suspend rosiglitazone (Avandia) from the European market. In US, rosiglitazone will be removed from the retail pharmacy stores by November 18th in 2011. [n this case, pioglitazone will be the only TZD-based drug available in the US and European markets. However, pioglitazone has been reported to increase risk for bladder cancer in two recent reports 2 ,3. In response, application of rosiglitazone has been suspended in the treatment of type 2 diabetes in some European counties (France and Italy) in June 2011. FDA in US has issued a warning to doctors and patients about the risk of bladder cancer from pioglitazone. Pioglitazone is the fourth drug in the thiazolidinedione class that has significant adverse clinical events: troglitazone (Rezulin) is the first with massive hepatic necrosis; muraglitazone (Pargluva, not marketed) and rosiglitazone (Avandia) are the second and third with increased cardiovascular events; and now pioglitazone is the fourth with bladder cancer. The risk of blander cancer may restrict pioglitazone application in the treatment of type 2 diabetes worldwide soon. It is now clear that a substitute for TZD is in demand for correction of insulin resistance in the treatment of type 2 diabetes. In this aspect, [ like to provide this review to facilitate our search for TZD substitute.
PPARy ligand

SyMhetic ligand
TZD is a synthetic ligand of the nuclear receptor PPARy (peroxisome proliferator-activated receptor gamma)' (Fig. I ). This class of insulin sensitizers include rosiglitazone (commercial name "Avandia" from GlaxoSmithKline, GSK), pioglitazone (Actos from Takeda Pharmaceuticals), muraglitazone, englitazone, ciglitazone and troglitazone s . Rosiglitazone binds to PPARy with a high affinity (K d of~40 nmoljL), whereas ioglitazone, englitazone, and ciglitazone were less potent hgands of PPARy. In vivo, activation of PPARy by these compounds is required for the insulin-sensitizing actions of the TZD-based drugs. Gene knockout studies in mice suggest that the PPARy activation in adipose tissue, skeletal muscle and macrophages are involved in the therapeutic activities of TZD for insulin sensitization. GW2570 is a very potent non-TZD PPARy-selective agonist that was recently shown to have anti· diabetic efficacy in humans s .
Fally acid ligand
Fatty acid and their derivatives are PPARy ligands (Fig. 1) . T~e search .for nat~ral ligands for PPARy begins with fatty aCids and ClcosanOids. Cell-based transactivation assays and direct binding studies are routinely used to characterize the endogenous activator of PPARy. Fatty acids and eicosanoid derivatives activate PPARy at micromolar concentrations. P~ARY pr.efers po~y.unsat~rated fatty acids, including the fatty aCids launc, palmitic, oleiC, and essential fatty acids linoleic acid, linolenic acid, arachidonic acid, 15d·PGJ2 (l5-deoxyDl2,14-prostaglandin J2) and eicosapentaenoic acid. Those fatty acids activate PPARy directly or act through a derivative such as nitrolinoleic acid 6 . Nitroalkene derivatives of linoleic acid (nitrolinoleic acid, LN02) are formed via nitric oxidedependent oxidative reactions and are found at concentrations of 500 nmol in the blood of healthy individuals. LN02 is able to bind to PPARy directly, and is more robust to activate PPARy than other endogenous PPARy ligands. LN02 induces PPARy-depend ent macrophage CD-36 expression, a~ip?cyte differentiation, and glucose uptake at a potency nvahng TZDs. These observations reveal that NO signal can be transduced by fatty acid nitration products and PPARdependent gene expression.
15d-PGJ2, a lipid metabolite, was the first endogenous ligand for PPARy discovered in laboratory. Although 15d-PGJ2 is the most potent natural ligand of PPARy in vitro, its effects remain to be determined in vivo. Two components of oxidized low density lipoprotein (ox-LDL), the 9-hydroxy and l3-hydroxy oct~decadienoic acids (HODE), are also potent endogenous activators ofPPARy. Activation of 12jl5-lipoxygenase induced by interleukin (IL)-4 also produced endogenous ligands 15- hydro~yei7osat.etraenoic acid (15-HETE) and l3-hYdroxy~cta decadlenolc aCId (13.HETE) for PPARy. However, it remains unknown if these natural ligands act as physiological PPARy ligands in vivo.
NSAIDs and PPARy
Non-steroidal anti-inflammatory drugs (NSAID) including indomethacin, ibuprofen, and fenoprofen have PPARy agonist activity at high drug concentrations7. Docosahexaenoic, a fish oil component, and 15d-P0J2 are two natural PPARy agonists 8 . These agents may inhibit inflammation through activation of PPARy as their blood concentration is sufficient to inhibit production of inflammatory cytokines, such as TNF-Il, IL-I and IL-6
9 • These agents were tested in fresh human blood monocytes. They suppress expression of pro-inflammatory cytokines in macrophages. They inhibit PMA or okadaic acid-induced, but not LPS-induced production of inflammatory cytokines. For inhibition of okadaic acid-induced cytokine production, potency and IC so of these NSAIDs are 15d-PGJ2 (2 Ilmol/L»troglitazone (10 IlmolfL» indomethacin (47IlmolfL»fenoprofen (l33Ilmol/L»ibupro-fen (l42Ilmol/L). These IC so concentrations are in the range of plasma concentrations under high-dose NSAID therapy, such as indomethacin (10 Ilmol/L), ibuprofen (300 IlmoL/L) and fenoprofen (250Ilmol/Lt Since PPARy may inhibit inflammatory cytokine in PPARy dependent and independent manners, the information suggests that PPAR may mediate NSAID activity to decrease inflammatory response. Inhibition of PO production by suppressing COXII, a NF-ICB target gene, will leads to pain relief. This hypothesis is supported by a recent study that NF-ICB interacts with PPARy through proteinprotein interaction and Leads to inhibition of PPARy funetion lO • These anti-inflammatory agents may activate PPARy indirectly by suppression of co-repressor ll .
PDtential TZD substitutes
3.J. HDAC inhibitor
PPARy function is inhibited by nuclear co-repressor in the absence of ligand (Fig. 2) . Upon ligand binding, the corepressor complex is replaced by coactivators leading to activation of PPARy. The corepressor contains catalytic subunit HDAC3 and regulatory subunit SMRT. In the study of inflammation in insulin resistance, we found that HDAC3 activity is enhanced in the nucleus by TNF-Il for PPARy inhibition ll . To block the HDAC3 activity, we used a HDAC inhibitor, sodium butyrate, in a mouse study to prevent inflammation-induced PPAR inhibition. We found that the HDAC inhibitor protects the mice from diet-induced insulin resistance 12 . The mechanism is related to stimulation of energy 139 expenditure by the HDAC inhibitor in mice. The same effects were observed for the classical HDAC inhibitor TSA in our study. The results suggest that HDAC inhibitor may be a new class of insulin sensitizer to substitute TZD (Fig. I) . Compared to TZD, HDAC inhibitor is not specific to a transcription factor. It is able to activate many transcription factors including PPARy. PPARoc, CREB and thyroid hormone receptor by inhibiting HDACs. This broad activity may be an advantage over a specific activator of PPARy. For example, the side effect of rosiglitazone in heart is associated with its high affinity to PPARy. Pioglitazone has less affinity to PPARy compared to rosiglitazone. Pioglitazone has fewer side effects in heart. These results suggest that a drug with low specificity to PPARy may be good alternative in the treatment of type 2 diabetes. An extension of this possibility is that a drug with multiple targets may be better than those with a single target. This possibility is supported by the HDAC inhibitor activity in the improvement of insulin sensitivity in mice l2 .
SJRTJ inhibitor
SIRTl, a class III HDAC, was shown to inhibit PPARy transcriptional activity at the target gene promoter l3 . Upon food withdrawal SIRTI protein binds to the PPARy-responsive genes, including those for fat synthesis, uptake and storage. SIRTI represses PPARy by docking with its cofactors NCoR (nuclear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptors). Mobilization of fatty acids from white adipocytes upon fasting is compromised in SIRTl+/-mice. Repression of PPARy by SIRTI is also evident in 3T3-L1 adipocytes, where overexpression of SIRTl attenuates adipogenesis, and RNA interference of SIRTI enhances it. In differentiated fat cells, up-regulation of SIRT I triggers lipolysis for loss of fat content. According to this observation, inhibition of SIRTl will enhanced PPARy function, and improves insulin sensitivity thereafter. However, this rational is challenged by the beneficial activities of SIRTI in others area, such as aging and liver steatosisl 4 . Inhibition of SIRTl activity may reduce lifespan and increase risk of fatty liver. It remains to be tested if SIRTI inhibitor is a good candidate for a new class of insulin sensitizer (Fig. I) . Figure 2 Mechanism of PPARy activation.
CREB inhibitor
A reduction in PPARy expression will decrease the transcriptional activity of PPARy. PPARy expression is inhibited by CREB (cAMP response element binding protein). Herzig et al. reported that CREB inhibited PPARy expression as CREB knockdown in vivo leads to 4-5 fold induction of PPARy mRNA IS . Mechanism analysis suggests that CREB inhibits PPARy through a transcriptional repressor, Hairy Enhancer of Split (HES-I). CREB induces HES-I and HES-I binds to the gene promoter of PPARy leading to the inhibition. According to this observation, inhibition of CREB should increase PPARy expression and PPARy function thereafter. However, CREB regulates many other genes that are required for metabolic homeostasis. CREB controls mitochondrial biogenesis through induction of PGC-Ia. expression 16 , and hepatic gluconeogenesis through PEPCK expression. Inhibition of CREB may have multiple effects in the body. It is not known if a CREB inhibitor can improve insulin sensitivity in vivo (Fig. I) .
Activator of p38 kinase
Regulation of PPARy activity by MAP kinase p38 was first indicated in a study when p38 modulators were used in the study of adipogenesis 17. Later studies confirm that p38 promotes PPARy transcription activity by several groups using different systems l 1l-20 . Regarding the molecular mechanism ofp38 activity, it was shown that p38 could phosphorylate PPARy coactivator (PGC-I) leading to enhancement of the transcriptional activity of PPARy on the VCP-I gene promoter 18 • p38 activity is required for VCP-l induction by rosiglitazone and retinoic acid in fetal brown adipocytes 21 . In addition to this possibility, other mechanisms have been proposed to explain p38 effect on the promotion of PPARy activity, such as induction of PPARy expression through NFATc4 19 and AFT2 interaction with PPARlo. Bone morphogenetic protein 2 (BMP2) promotes the differentiation of undifferentiated mesenchymal cells into adipocytes. This activity of BMP2 is blocked by p38 kinase inhibitor. The mechanism is that the transcriptional activity of PPARy induced by BMP is blocked by p38 inhibitor 2o . Activation of p38 kinase by overexpression of TAKI and TABI did not affect PPARy expression, but led to the up-regulation of transcriptional activity of PPARy2o. In discussion, Hata expressed that "the mechanism for the up-regulation of PPARy by p38 kinase remains unknown". The direct upregulation of PPARy by p38 kinase through phosphorylation is unlikely beCau.ge PPARy possesses only one consensus phosphorylation site by MAP kinases at serine I 12, which is shown to be phosphorylated by ERK (extracellular signalregulated kinase). that inhibits the transcriptional activity of PPARy22. ATF-2 may mediate p38 activity as ATF-2 is regulated by p38 kinase. In indomethacin-treated cells. activation ofPPARy is associated with activation ofp38 23 , suggesting that p38 may mediate indomethacin signal for activation of PPARy. Rosiglitazone (Rosi), as well as retinoic acids 9-dsretinoic acid and all-trans-retinoic acid have "extragenic" effects on fetal primary brown adipocytes and induce p38 mitogen-activated protein kinase (p38 MAPK) activation 21 . Based on this activity of p38, it is expected that p38 activator Jian-ping Ye Figure 3 Potential TZD substitutes.
should enhance PPARy function (Fig. 3) . However, p38 activation may have side effects such as risk of atherosclerosis. Activation of the p38 MAP kinase pathway is required for foam cell formation from macroph.ages exposed to oxidized LDL24. Foam cell is the major cell typein the atherosclerosis lesion.
ERK inhibitor
Persistent activation of ERK was shown to inhibit PPARy activity through a direct phosphorylation 22 ( Fig. I) . Persistent increase in ERK activity leads to the inhibition of PPARy function in the tyrosine kinases-l (Dokl) KO mice 2s . However, it was shown that transient activation of MEK/ERK signaling promotes PPARy activity during the differentiation of 3T3-Ll preadipocytes 26 . It is not clear if an ERK inhibitor will be able to enhance PPARy function in vivo. If it does, it may be worth to test its activity in the regulation of insulin resistivity.
NO inducer
NO may enhance PPARy function through generation of nitrolipid (Fig. I) . Nitrolinoleic acid (LN02) is a product of linoleic acid after reaction with NO (Nitric Oxide). Nitrolinoleic acid was reported to be a ligand ofPPARy6. Additionally. NO may activate PPARy through activation of cGMP. NO was reported to increase energy expenditure through a signaling pathway of cOMP-PPARy-PGC-I-UCPI 27 . In the study, eNOS-/-mouse was used and NO effect was observed in cells including 3T3-Ll adipocytes. It was shown that NO can activate the cOMP signaling pathway in 3T3-Ll adipocyte. monocytes and other types of cells 27 . PPARy activity is enhanced by NO donors S-nitrosoacetylpenicillamine (SNAP. 100 Ilmol/L). S-nitroso-L-glutathione (OSNO) and cGMP analog 8Br-cGMP (I mmoI/L). The activity is reduced by NO scavenger oxyhemoglobin (5011moI/L). nitric oxide synthase (NOS) inhibitor L-NAME, and selective guanylatecyclase inhibitor I H-[1. 2, 4] oxadiazolo [4.3-a] quinoxalin-l·one (ODQ. I~moI/L). These data suggest that NO inducer may activate PPARy.
Cdk5 inhibitor
It has been reported recently that Cdk5 (cyclin-dependent kinase 5) inhibits PPARy function in insulin sensitization (Fig. 1)28 . Cdk5 is extensively studied in the neuronal cells. Cdk5 is involved in the regulation of various physiological processes of neuronal cells from survival. migration and differentiation, to synaptogenesis, synaptic plasticity and neurotransmission. Dysregulation of Cdk5 has been demonstrated to playa critical role in the pathogenic process of neurodegenerative disorders, such as Alzheimer's disease. A new study reports that Cdk5 is activated in adipocytes in mice by high-fat diet 2B . In this study, Cdk5 is shown to phosphorylate the nuclear receptor PPARy at serine 273 leading to dysregulation of a large number of genes in obesity including adiponectin. The phosphorylation of PPARy by Cdk5 is blocked by rosiglitazone. This inhibition works both in vivo and in vitro, and is completely independent of gene transcription from PPARy activation. The inhibition is tightly associated with the anti-diabetic effects of rosiglitazone. These findings suggest that Cdk5-mediated phosphorylation of PPARy may be involved in the pathogenesis of insulin resistance, and present an opportunity for development of new class of anti-diabetic drugs from Cdk inhibitors. These possibilities remain to be tested in vivo.
3.8, PPARy is required/or adipose /issue growth
PPARy is most abundant in fat tissues, and dysfunction of PPARy contributes to insulin resistance. The nuclear receptor PPARy is a member of peroxisome proliferator-activated receptor (PPAR) family that includes PPARa, PPARy, and PPARIi (pPAR13). There are two isoforms in PPARy, PPARyl and PPARy2. PPARyl is expressed ubiquitously and PPARy2 is mainly expressed in adipocytes. The biological activities ofPPARy are very broad, but it is generally accepted for a master transcriptional regulator of lipid and glucose metabolism. Activation of PPARy promotes adipocyte differentiation and triglyceride accumulation in adipocytes. Gene knockout studies consistently suggest that PPARy is required for adipose tissue development and the tissue growth in response to positive energy balance. Four groups independently made fat-specific knockout (KO) mice and published the metabolic phenotypes of the mice all in PNAS2~32. The studies suggest that PPARy KO in fat prevents obesity and insulin resistance in the mice fed a high-fat diet. In the last report, the mice have an increase in food intake, spontaneous physical activity and energy expenditure 32 . The increased energy expenditure may provide protection against obesity and insulin resistance in the mice. The energy expenditure is likely a result of increased supply of fatty acids to mitochondria since the adipose tissues do not have sufficient room to store the fatty acids. The study suggests that restriction of PPARy function before obesity may promote energy expenditure and prevent development of dietary obesity leading to preservation of insulin sensitivity. However, activation of PPARy induces generation of new adipocyte through preadipocyte differentiation to increase storage capacity of adipose tissue. This action in adipose tissue allows PPARy agonist to improve insulin sensitivity by reducing blood lipids and preventing ectopic fat deposition, which induces lipotoxicity in liver and skeletal muscle in the pathogenesis of insulin resistance. Activation of PPARy in adipo'se tissue is the molecular mechanism by which PPARy ligand improve insulin sensitivity in patients.
Summary
Current literature suggests that TZD-based drugs are facing more and more challenges from the severe side effects in the 141 cardiovascular system and bladder cancer. There have been four TZD-based drugs and all of them have life-threatening side effects. Although tbe side effects are different among the four drugs, the history of TZD-based drugs suggests that this class of insulin sensitizer will reach their end sooner or later.
With prevalence of type 2 diabetes and limited number of insulin sensitizers, there is a huge demand for a new class of drug that is better than TZDs in safety. In this review, several approaches are discussed in search for the new class of drugs. These include HDAC inhibitor, SIRTl inhibitor, Cdk5 inhibitor, ERK inhibitor, CREB inhibitor and p38 activator (Fig. 3) . It appears that a HDAC inhibitor holds a strong promise, It improves insulin sensitivity, stimulates energy expenditure and suppresses cancer. This example suggests that a drug for multiple targets may be better than those for a single target in the treatment of insulin resistance and type 2 diabetes.
